Vantia Therapeutics Appoints Andrew Crockett as Vice President Business Development
Vantia Therapeutics announced the appointment of Andrew Crockett as Vice President business development.
Andrew joins Vantia from the US specialty pharma company ZARS Pharma where he was most recently Vice President Business Development. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including merger and acquisitions, national and international product licences, IP and technology licences, and R&D alliances.
Andrew has studied at Harvard Business School and also holds an MBA from The Wharton School, University of Pennsylvania, with a major in Finance. He has served as an advisor to various investment groups for the medical device and pharmaceutical industries and is an advisory board member for US-based start ups.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.